US OptionsDetailed Quotes
PFE241220P24000
- 0.01
- -0.11-91.67%
15min DelayTrading Dec 17 11:21 ET
0.03High0.01Low
0.01Open0.12Pre Close665 Volume51.91K Open Interest24.00Strike Price910.00Turnover51.47%IV8.33%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type-0.0302Delta0.0543Gamma1744.67Leverage Ratio-0.0106Theta-0.0001Rho-52.66Eff Leverage0.0017Vega
Pfizer Stock Discussion
Sign in to post a comment
$Pfizer (PFE.US)$ can you maintain up?😴😴😴
1
1
$Pfizer (PFE.US)$
Next year 2025, the pharma stocks will be the winners. Pfizer will be one of them. Now it is undervalued and oversold. I will hold long and watch it to rise high next year. Covid is here to stay and no way to eradicate it. Vaccines will always be needed no matter what.
Next year 2025, the pharma stocks will be the winners. Pfizer will be one of them. Now it is undervalued and oversold. I will hold long and watch it to rise high next year. Covid is here to stay and no way to eradicate it. Vaccines will always be needed no matter what.
3
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Pfizer (PFE.US)$
Pfizer CEO Says "Developed a Good Relationship" With Hhs Nominee Kennedy During Dinner With Trump -Conf Call.
Pfizer CEO Says "Developed a Good Relationship" With Hhs Nominee Kennedy During Dinner With Trump -Conf Call.
7
Morning Movers
Gapping up
$Pfizer (PFE.US)$ stock rose 2.9% after the drugmaker said it was expecting its 2025 profits to be nearly in line with expectations, with the company reining in costs and cutting debt by shedding non-core businesses as its rebuilds itself post a sharp slump in sales of COVID-19 products.
$Coinbase (COIN.US)$ stock rose 0.8% and $MicroStrategy (MSTR.US)$ stock climbed 0.7%, with the crypto-focused stocks ra...
Gapping up
$Pfizer (PFE.US)$ stock rose 2.9% after the drugmaker said it was expecting its 2025 profits to be nearly in line with expectations, with the company reining in costs and cutting debt by shedding non-core businesses as its rebuilds itself post a sharp slump in sales of COVID-19 products.
$Coinbase (COIN.US)$ stock rose 0.8% and $MicroStrategy (MSTR.US)$ stock climbed 0.7%, with the crypto-focused stocks ra...
17
3
4
$Pfizer (PFE.US)$ People like you and me can make money in so many other stocks. But if you invest in Pfizer you invest in your own death. This is just my personnel opinion. I know keep emotions out of market but not in this case for me. I don’t care stock price of such companies whether it goes up or down. I will not put penny in such companies. They sell death. Never invest in Vaccine companies again. Boycott everyone of them.
4
7
$Pfizer (PFE.US)$
Pfizer Inc. (NYSE:PFE) today provided its full-year 2025 guidance(1) and reaffirmed its October 29, 2024 full-year 2024 guidance(1) . The accompanying presentation can be found at .
Full-Year 2025 Revenue Guidance(1)
Pfizer anticipates full-year 2025 revenues to be in the range of $61.0 to $64.0 billion, which includes the expectation of revenues from our COVID-19 products in 2025 being largely consistent with 2024 after excluding approximately $1.2 billion of non-recurring reve...
Pfizer Inc. (NYSE:PFE) today provided its full-year 2025 guidance(1) and reaffirmed its October 29, 2024 full-year 2024 guidance(1) . The accompanying presentation can be found at .
Full-Year 2025 Revenue Guidance(1)
Pfizer anticipates full-year 2025 revenues to be in the range of $61.0 to $64.0 billion, which includes the expectation of revenues from our COVID-19 products in 2025 being largely consistent with 2024 after excluding approximately $1.2 billion of non-recurring reve...
2
1
$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...
10
1
4
$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...
+4
6
9
1
No comment yet
Deep Sea : If the big players are willing to push up the stock, it will rise and maintain. The outlook for Pfizer for next year 2025 is brighter and clearer, given that the additional cost cutting of 500 million USD and deleverging of debt next year as mentioned by CEO.